JY
CUE icon

Jeff Yass’s Cue Biopharma CUE Stock Holding History

Jeff Yass’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-373
Closed -$12.2K – 12613
2024
Q4 		$12.2K Buy
+373
New +$14K ﹤0.01% 11971
2024
Q3 		– Sell
-1,443
Closed -$53.7K – 12136
2024
Q2 		$53.7K Buy
+1,443
New +$71.4K ﹤0.01% 11381
2024
Q1 		– Sell
-2,530
Closed -$200K – 12340
2023
Q4 		$200K Buy
+2,530
New +$181K ﹤0.01% 10683
2023
Q1 		– Sell
-980
Closed -$83.8K – 12677
2022
Q4 		$83.8K Buy
980
+390
+66% +$35.7K ﹤0.01% 11096
2022
Q3 		$39K Buy
590
+23
+4% +$1.98K ﹤0.01% 12343
2022
Q2 		$42K Sell
567
-3,430
-86% -$401K ﹤0.01% 12068
2022
Q1 		$585K Buy
3,997
+1,397
+54% +$296K ﹤0.01% 8572
2021
Q4 		$882K Sell
2,600
-107
-4% -$41.4K ﹤0.01% 7619
2021
Q3 		$1.18M Buy
2,707
+1,594
+143% +$556K ﹤0.01% 7116
2021
Q2 		$389K Buy
1,113
+700
+169% +$271K ﹤0.01% 10202
2021
Q1 		$151K Buy
+413
New +$170K ﹤0.01% 11650
2020
Q4 		– Sell
-553
Closed -$250K – 11086
2020
Q3 		$250K Sell
553
-1,004
-64% -$579K ﹤0.01% 9066
2020
Q2 		$1.15M Buy
+1,557
New +$1.13M ﹤0.01% 5604

Other funds holding CUE

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM

Jeff Yass's CUE Position: Q2 2026 in Review

Jeff Yass increased its Cue Biopharma (CUE) stake by 1,242% in Q2 2026, buying an estimated $230K and bringing the position to 11,003 shares worth $347K. The position accounts for ﹤0.01% of the portfolio, ranked #10734.

Jeff Yass first reported a position in CUE in Q2 2020 and has held it in 22 quarters since. The position peaked at $689K in Q1 2021. 49 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • Jeff Yass held 11,003 shares of Cue Biopharma worth $347K as of Q2 2026.
  • Jeff Yass bought 10,183 Cue Biopharma shares in Q2 2026, an estimated $230K.
  • Cue Biopharma made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10734 holding.
  • Jeff Yass first reported a position in Cue Biopharma in Q2 2020 and has held it in 22 quarters since.
  • Jeff Yass's Cue Biopharma position peaked at $689K in Q1 2021.
  • 49 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.